Heart failure and cardiac hypertrophy

被引:18
|
作者
Rame J.E. [1 ]
Dries D.L. [1 ]
机构
[1] Division of Cardiology, University of California San Francsiso, San Francisco, CA 94143-0124
关键词
Heart Failure; Left Ventricular Hypertrophy; Losartan; Carvedilol; Main Drug Interaction;
D O I
10.1007/s11936-007-0024-3
中图分类号
学科分类号
摘要
Left ventricular failure is the final common pathway for a wide spectrum of myocardial insults, including systemic hypertension and myocardial infarction. Although left ventricular hypertrophy is an adaptive response to pressure and volume overload, this process becomes maladaptive if left untreated and pathologic cardiac hypertrophy then becomes an important and independent risk factor for the development of heart failure. Despite its importance, the transition from hypertrophy to heart failure in humans is poorly understood. The focus of treatment should be prevention of heart failure and other cardiovascular events, such as stroke and atrial fibrillation. When heart failure is present, treatment with medical and device therapy is then focused on improving functional capacity, increasing survival, and preventing progression to end-stage heart failure. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:289 / 301
页数:12
相关论文
共 50 条
  • [21] β-adrenergic receptor desensitization in cardiac hypertrophy and heart failure
    Choi, DJ
    Rockman, HA
    CELL BIOCHEMISTRY AND BIOPHYSICS, 1999, 31 (03) : 321 - 329
  • [22] Cardiac metabolism in hypertrophy and heart failure: implications for therapy
    N. Siddiqi
    S. Singh
    R. Beadle
    D. Dawson
    M. Frenneaux
    Heart Failure Reviews, 2013, 18 : 595 - 606
  • [23] Arrhythmogenesis in cardiac hypertrophy and heart failure - experimental findings
    Milberg, P.
    Pott, C.
    Eckardt, L.
    Breithardt, G.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2008, 133 (50) : S285 - S289
  • [24] Alterations in mitochondrial function in cardiac hypertrophy and heart failure
    Moritz Osterholt
    T. Dung Nguyen
    Michael Schwarzer
    Torsten Doenst
    Heart Failure Reviews, 2013, 18 : 645 - 656
  • [25] Targeting Cardiac Hypertrophy: Toward a Causal Heart Failure Therapy
    Bisping, Egbert
    Wakula, Paulina
    Poteser, Michael
    Heinzel, Frank R.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2014, 64 (04) : 293 - 305
  • [26] Myofibrillar remodelling in cardiac-hypertrophy, heart failure and cardiomyopathies
    Machackova, Jarmila
    Barta, Judit
    Dhalla, Naranjan S.
    CANADIAN JOURNAL OF CARDIOLOGY, 2006, 22 (11) : 953 - 968
  • [27] Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development
    Caturano, Alfredo
    Vetrano, Erica
    Galiero, Raffaele
    Salvatore, Teresa
    Docimo, Giovanni
    Epifani, Raffaella
    Alfano, Maria
    Sardu, Celestino
    Marfella, Raffaele
    Rinaldi, Luca
    Sasso, Ferdinando Carlo
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (05)
  • [28] Oxidative stress and redox signalling in cardiac hypertrophy and heart failure
    Seddon, Mike
    Looi, Yee H.
    Shah, Ajay M.
    HEART, 2007, 93 (08) : 903 - 907
  • [29] Role of Irisin in Myocardial Infarction, Heart Failure, and Cardiac Hypertrophy
    Ho, Ming-Yun
    Wang, Chao-Yung
    CELLS, 2021, 10 (08)
  • [30] CARDIAC HYPERTROPHY AND HEART-FAILURE IN GUINEA-PIGS
    CALVELEY, SB
    PATHOLOGY, 1973, 5 (01) : 79 - 79